Multidisciplinary management, standards of care, optimal diagnostics, therapies and future perspectives in the care of Lymphoma patients in sub-Saharan Africa.

Lead Faculty: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist

Executive Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com

Website: www.intercancer.com

This educational activity is provided by the International Cancer Institute (ICI)

Faculty

1. Prof. Riyat Malkit- Consultant Hematologist
2. Dr. Shaheen Sayed- Anatomic Pathologist
3. Dr. Zipporah Ali- Palliative Care Specialist
4. Dr. Anthony Betbadal– Adult Hematologist
5. Dr. Njoki Njiraini-Clinical Oncologist
6. Dr. Hussein Elias– Palliative Care Specialist/Family Medicine

This course will be accredited by:

Target Audience

The primary target audience for this course comprises the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; Oncology pharmacists; Oncology PharmTechs; Oncology clinical officers; physician assistants; and other allied health care professionals.

LEARNING OBJECTIVES

At the end of this educational activity, participants should be able to:

1. To learn about lymphoma outcome data in Kenya and sub-Saharan Africa (SSA)
2. To highlight the pathological basis of lymphoma classification
3. To understand the role of the multidisciplinary team in lymphoma management
4. To understand the role of PET in staging, re-staging and follow-up
5. To review the treatment strategy for the most common lymphoma types
6. To understand the management of lymphomas in HIV populations
7. To understand the role of Palliative and supportive care in lymphoma management
8. To discuss clinical cases between faculty and participants

Disclosure of Conflicts of Interest

International Cancer Institute (ICI) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labelled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit.

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

The Program

LECTURES

1. Orientation to the course (Chite) Monday 11th May 2020 4:00-4:30 PM EAT
2. Lymphoma Data in Kenya and SSA (Chite) Wednesday 13th May 2020 4:00-5:30 PM EAT
3. Pathologic basis of lymphoma Classification (Shaheen) 18th May 2020 4:00-5:30 PM EAT
4. Approach to the management of a Lymphoma Patient (Riyat) 20th May 2020 4:00-5:30 PM EAT
5. Treatment of Lymphoma I (Njoki) 25th May 2020 4:00-5:30 PM EAT
6. Treatment of Lymphoma II (Betbadal) 27th May 2020 4:00-5:30 PM EAT
7. Role of PET/CT in management of Lymphoma (Riyat) 1st June 2020 4:00-5:30 PM EAT
8. Role of Radiotherapy in the management of Lymphoma (Njoki) 3rd June 2020 4:00-5:30 PM EAT
9. Management of lymphomas in HIV, HBV/HCV, Pregnant and Geriatric populations (Chite) 8th June 2020 4:00-5:30 PM EAT
10. Stem Cell Transplant in Lymphoma (Betbadal) 10th June 2020 4:00-5:30 PM EAT
11. Supportive and Palliative care in Lymphoma (Zippy and Hussein) 15th June 2020 4:00-5:30 PM EAT
12. Clinical cases in Lymphoma Management (Riyat and Chite) 17th June 2020 4:00-5:30 PM EAT

 

Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours)

All those interested in registration to this course, please send your information to info@intercancer.com

Acknowledgements

ICI Acknowledges that the funding for this preceptorship training has been proudly supported by the Roche as part of ICI_Roche Shining Tower Project (STP).